Logo image of RCAT

RED CAT HOLDINGS INC (RCAT) Stock Fundamental Analysis

USA - NASDAQ:RCAT - US75644T1007 - Common Stock

10.99 USD
-0.01 (-0.09%)
Last: 9/12/2025, 8:11:50 PM
11.15 USD
+0.16 (+1.46%)
Pre-Market: 9/15/2025, 9:07:32 AM
Fundamental Rating

3

Overall RCAT gets a fundamental rating of 3 out of 10. We evaluated RCAT against 125 industry peers in the Electronic Equipment, Instruments & Components industry. While RCAT seems to be doing ok healthwise, there are quite some concerns on its profitability. RCAT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RCAT has reported negative net income.
RCAT had a negative operating cash flow in the past year.
RCAT had negative earnings in each of the past 5 years.
RCAT had a negative operating cash flow in each of the past 5 years.
RCAT Yearly Net Income VS EBIT VS OCF VS FCFRCAT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

The Return On Assets of RCAT (-55.70%) is worse than 87.20% of its industry peers.
RCAT has a worse Return On Equity (-70.74%) than 77.60% of its industry peers.
Industry RankSector Rank
ROA -55.7%
ROE -70.74%
ROIC N/A
ROA(3y)-36.1%
ROA(5y)-55.7%
ROE(3y)-39.94%
ROE(5y)-95.13%
ROIC(3y)N/A
ROIC(5y)N/A
RCAT Yearly ROA, ROE, ROICRCAT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K 2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RCAT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RCAT Yearly Profit, Operating, Gross MarginsRCAT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 0 0 0 0 0 0 0 0 0 0

More info and screens

5

2. Health

2.1 Basic Checks

RCAT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RCAT has more shares outstanding
The number of shares outstanding for RCAT has been increased compared to 5 years ago.
The debt/assets ratio for RCAT has been reduced compared to a year ago.
RCAT Yearly Shares OutstandingRCAT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
RCAT Yearly Total Debt VS Total AssetsRCAT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

RCAT has an Altman-Z score of 23.18. This indicates that RCAT is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of RCAT (23.18) is better than 97.60% of its industry peers.
RCAT has a Debt/Equity ratio of 0.20. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.20, RCAT perfoms like the industry average, outperforming 48.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Altman-Z 23.18
ROIC/WACCN/A
WACC9.31%
RCAT Yearly LT Debt VS Equity VS FCFRCAT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

RCAT has a Current Ratio of 3.80. This indicates that RCAT is financially healthy and has no problem in meeting its short term obligations.
RCAT's Current ratio of 3.80 is fine compared to the rest of the industry. RCAT outperforms 75.20% of its industry peers.
A Quick Ratio of 2.92 indicates that RCAT has no problem at all paying its short term obligations.
The Quick ratio of RCAT (2.92) is better than 73.60% of its industry peers.
Industry RankSector Rank
Current Ratio 3.8
Quick Ratio 2.92
RCAT Yearly Current Assets VS Current LiabilitesRCAT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for RCAT have decreased strongly by -17.31% in the last year.
The Revenue for RCAT has decreased by -53.12% in the past year. This is quite bad
Measured over the past years, RCAT shows a very strong growth in Revenue. The Revenue has been growing by 176.68% on average per year.
EPS 1Y (TTM)-17.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
Revenue 1Y (TTM)-53.12%
Revenue growth 3Y52.8%
Revenue growth 5Y176.68%
Sales Q2Q%-18.11%

3.2 Future

The Earnings Per Share is expected to grow by 39.49% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 123.37% on average over the next years. This is a very strong growth
EPS Next Y-7.95%
EPS Next 2Y49.03%
EPS Next 3Y39.49%
EPS Next 5YN/A
Revenue Next Year321.55%
Revenue Next 2Y191%
Revenue Next 3Y123.37%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
RCAT Yearly Revenue VS EstimatesRCAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M
RCAT Yearly EPS VS EstimatesRCAT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 -0.4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RCAT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 124.32 indicates a quite expensive valuation of RCAT.
The rest of the industry has a similar Price/Forward Earnings ratio as RCAT.
The average S&P500 Price/Forward Earnings ratio is at 22.73. RCAT is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 124.32
RCAT Price Earnings VS Forward Price EarningsRCAT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCAT Per share dataRCAT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A more expensive valuation may be justified as RCAT's earnings are expected to grow with 39.49% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.03%
EPS Next 3Y39.49%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RCAT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RED CAT HOLDINGS INC

NASDAQ:RCAT (9/12/2025, 8:11:50 PM)

Premarket: 11.15 +0.16 (+1.46%)

10.99

-0.01 (-0.09%)

Chartmill FA Rating
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)09-23 2025-09-23
Inst Owners18.24%
Inst Owner Change58.85%
Ins Owners14.17%
Ins Owner Change-0.11%
Market Cap1.10B
Analysts84.44
Price Target15.64 (42.31%)
Short Float %20.52%
Short Ratio1.98
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-89.99%
Min EPS beat(2)-152.1%
Max EPS beat(2)-27.88%
EPS beat(4)0
Avg EPS beat(4)-100.39%
Min EPS beat(4)-152.1%
Max EPS beat(4)-27.88%
EPS beat(8)1
Avg EPS beat(8)-86.46%
EPS beat(12)2
Avg EPS beat(12)-132.75%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-46.29%
Min Revenue beat(2)-59.15%
Max Revenue beat(2)-33.43%
Revenue beat(4)0
Avg Revenue beat(4)-25.15%
Min Revenue beat(4)-59.15%
Max Revenue beat(4)-1.15%
Revenue beat(8)2
Avg Revenue beat(8)-16.41%
Revenue beat(12)3
Avg Revenue beat(12)-25.46%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)15%
PT rev (3m)15%
EPS NQ rev (1m)-116.67%
EPS NQ rev (3m)-18.18%
EPS NY rev (1m)-5.83%
EPS NY rev (3m)-41.11%
Revenue NQ rev (1m)-15.8%
Revenue NQ rev (3m)-52.43%
Revenue NY rev (1m)-4.54%
Revenue NY rev (3m)-4.39%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 124.32
P/S 158.39
P/FCF N/A
P/OCF N/A
P/B 11.47
P/tB 15.61
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)0.09
Fwd EY0.8%
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.47
OCFYN/A
SpS0.07
BVpS0.96
TBVpS0.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -55.7%
ROE -70.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.1%
ROA(5y)-55.7%
ROE(3y)-39.94%
ROE(5y)-95.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.37%
Cap/Sales 9.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.8
Quick Ratio 2.92
Altman-Z 23.18
F-Score3
WACC9.31%
ROIC/WACCN/A
Cap/Depr(3y)137.29%
Cap/Depr(5y)N/A
Cap/Sales(3y)10.59%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
EPS Next Y-7.95%
EPS Next 2Y49.03%
EPS Next 3Y39.49%
EPS Next 5YN/A
Revenue 1Y (TTM)-53.12%
Revenue growth 3Y52.8%
Revenue growth 5Y176.68%
Sales Q2Q%-18.11%
Revenue Next Year321.55%
Revenue Next 2Y191%
Revenue Next 3Y123.37%
Revenue Next 5YN/A
EBIT growth 1Y-73.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2.63%
EBIT Next 3Y56.58%
EBIT Next 5YN/A
FCF growth 1Y-152.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-154.15%
OCF growth 3YN/A
OCF growth 5YN/A